Media

Intervacc – Interim Report January – June 2026

Oncopeptides – Invitation to presentation of the Q2 report 2026

Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides CorporateUpdates

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac